Locally Advanced Or Metastatic Solid Tumors clinical trials

Explore recruiting locally advanced or metastatic solid tumors clinical trials.

Recruiting locally advanced or metastatic solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Or Metastatic Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

J2G-OX-Y001 - A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Italy, France, Poland, Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

Spain, France, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

Spain, Ireland, Italy, France, Romania

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

HERTHENA-PanTumor01: A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd) in Subjects with Locally Advanced or Metastatic Solid Tumors

Belgium, France, Spain, Germany, Hungary, Italy +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors

Belgium, Spain, France, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors

Denmark, Spain, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Locally Advanced Or Metastatic Solid Tumors trials by city

Locally Advanced Or Metastatic Solid Tumors in Toronto Locally Advanced Or Metastatic Solid Tumors in Vancouver Locally Advanced Or Metastatic Solid Tumors in Montreal Locally Advanced Or Metastatic Solid Tumors in Calgary Locally Advanced Or Metastatic Solid Tumors in Edmonton Locally Advanced Or Metastatic Solid Tumors in Ottawa Locally Advanced Or Metastatic Solid Tumors in Winnipeg Locally Advanced Or Metastatic Solid Tumors in Quebec City Locally Advanced Or Metastatic Solid Tumors in Hamilton Locally Advanced Or Metastatic Solid Tumors in Kitchener Locally Advanced Or Metastatic Solid Tumors in London Locally Advanced Or Metastatic Solid Tumors in Halifax Locally Advanced Or Metastatic Solid Tumors in New York Locally Advanced Or Metastatic Solid Tumors in Los Angeles Locally Advanced Or Metastatic Solid Tumors in Chicago Locally Advanced Or Metastatic Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease